Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Andrew J. Carroll"'
Autor:
Jessica Kohlschmidt, Richard Stone, Dimitrios Papaioannou, Clara D. Bloomfield, Adrienne M. Dorrance, Marius Bill, Bayard L. Powell, Andrew J. Carroll, Deedra Nicolet, Jonathan E. Kolitz, Ramiro Garzon, John C. Byrd, Ann-Kathrin Eisfeld, Zachary Brannan, Xiaoqing Rong-Mullins, Krzysztof Mrózek, Kellie J. Archer, Christopher J. Walker
Publikováno v:
Haematologica
Leukemia stem cells (LSC) are more resistant to standard chemotherapy and their persistence during remission can cause relapse, which is still one of the major clinical challenges in the treatment of acute myeloid leukemia (AML). A better understandi
Autor:
James S. Blachly, Andrew J. Carroll, John C. Byrd, Christopher C. Oakes, Sydney Fobare, Shelley Orwick, Richard Stone, Krzysztof Mrózek, Alice S. Mims, Eunice S. Wang, Hatice Gulcin Ozer, Bayard L. Powell, Ann-Kathrin Eisfeld, Jonathan E. Kolitz, Ramiro Garzon, Jessica Kohlschmidt, Deedra Nicolet, Erin Hertlein
Publikováno v:
Blood advances. 6(5)
Prognostic factors associated with chemotherapy outcomes in patients with acute myeloid leukemia (AML) are extensively reported, and one gene whose mutation is recognized as conferring resistance to several newer targeted therapies is protein tyrosin
Autor:
Marius Bill, Bayard L. Powell, John C. Byrd, Brian Giacopelli, Jessica Kohlschmidt, Jonathan E. Kolitz, Dimitrios Papaioannou, Christopher C. Oakes, Ramiro Garzon, Krzysztof Mrózek, Richard Stone, Andrew J. Carroll, Ann-Kathrin Eisfeld, Deedra Nicolet, Clara D. Bloomfield
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-4 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-4 (2021)
Recently, a novel knowledge bank (KB) approach to predict outcomes of individual patients with acute myeloid leukemia (AML) was developed using unbiased machine learning. To validate its prognostic value, we analyzed 1612 adults with de novo AML trea
Autor:
Clara D. Bloomfield, Bayard L. Powell, Andrew J. Carroll, Shelley Orwick, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Bhavana Bhatnagar, Dimitrios Papaioannou, Richard Stone, Deedra Nicolet, Krzysztof Mrózek, John C. Byrd, Jonathan E. Kolitz, Christopher J. Walker, James S. Blachly
Publikováno v:
Leukemia. 34:358-368
Sole trisomies of chromosomes 4, 8, 11, 13 and 21 account for 89–95% of all sole trisomies in adult AML patients. We analyzed clinical and molecular characteristics of 138 de novo AML patients with sole +4, +8, +11, +13 or +21, and compared them wi
Autor:
Jonathan E. Kolitz, William Blum, Christopher J. Walker, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, James S. Blachly, Dimitrios Papaioannou, Deedra Nicolet, Geoffrey L. Uy, Eunice S. Wang, Marius Bill, Richard Stone, Krzysztof Mrózek, Bayard L. Powell, Clara D. Bloomfield, Andrew J. Carroll, John C. Byrd
Publikováno v:
Leukemia
Complex karyotype (CK) with ≥ 3 abnormalities is detected in 10–12% of patients with acute myeloid leukemia (AML) and associated with poor prognosis. The most common unbalanced abnormalities found in CK result in loss of material from the 5q, 7q,
Autor:
Brian Giacopelli, Markus Scholz, Pamela Brock, Sebastian Schwind, Andrew J. Carroll, Marius Bill, Christopher C. Oakes, John C. Byrd, Dietger Niederwieser, Christopher J. Walker, Richard Stone, Krzysztof Mrózek, Eunice S. Wang, Ann-Kathrin Eisfeld, Jonathan E. Kolitz, Clara D. Bloomfield, Bayard L. Powell, Luke K Genutis, Sandya Liyanarachchi, Albert de la Chapelle, Jessica Kohlschmidt, Deedra Nicolet
Publikováno v:
Leukemia. 33:771-775
Autor:
Bayard L. Powell, Bhavana Bhatnagar, Alice S. Mims, Isaiah Boateng, Deedra Nicolet, Richard Stone, James S. Blachly, Shelley Orwick, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, Albert de la Chapelle, Sophia E. Maharry, Jonathan E. Kolitz, Ramiro Garzon, Andrew J. Carroll, John C. Byrd, James L. Fisher, Krzysztof Mrózek, Electra D. Paskett, Brian Giacopelli, Qiuhong Zhao, Christopher C. Oakes, Christopher J. Walker
Publikováno v:
Cancer Discov
Clinical outcome of patients with acute myeloid leukemia (AML) is associated with cytogenetic and molecular factors and patient demographics (e.g., age and race). We compared survival of 25,523 non-Hispanic Black and White adults with AML using Surve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d28d2bb84fbfcea7e33723db08a26f1
https://europepmc.org/articles/PMC7933110/
https://europepmc.org/articles/PMC7933110/
Autor:
James S. Blachly, Marius Bill, Clara D. Bloomfield, Christopher J. Walker, Bayard L. Powell, Krzysztof Mrózek, Albert de la Chapelle, Jonathan E. Kolitz, Andrew J. Carroll, Ann-Kathrin Eisfeld, Deedra Nicolet, Jessica Kohlschmidt, Shelley Orwick, Dimitrios Papaioannou, Richard Stone, John C. Byrd
Publikováno v:
Proc Natl Acad Sci U S A
Balanced rearrangements involving the KMT2A gene, located at 11q23, are among the most frequent chromosome aberrations in acute myeloid leukemia (AML). Because of numerous fusion partners, the mutational landscape and prognostic impact of specific 11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ddd7c0376dafdd23a8891fb03074d32
https://europepmc.org/articles/PMC7584992/
https://europepmc.org/articles/PMC7584992/
Autor:
James S. Blachly, Ann-Kathrin Eisfeld, Richard Stone, Christopher J. Walker, Krzysztof Mrózek, Albert de la Chapelle, Bayard E. Powell, Andrew J. Carroll, Alice S. Mims, Deedra Nicolet, Jessica Kohlschmidt, Jonathan E. Kolitz, Dimitrios Papaioannou, Clara D. Bloomfield, John C. Byrd
Publikováno v:
Leukemia
The European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) have become an important tool to assess patients’ prognosis and guide treatment. We tested the prognostic impact of the 2017 ELN classificat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::899263e881c301e0751b5213e0cae6d1
https://europepmc.org/articles/PMC7882079/
https://europepmc.org/articles/PMC7882079/
Autor:
Deedra Nicolet, John C. Byrd, Sumithira Vasu, Klaus H. Metzeler, Joseph O. Moore, Krzysztof Mrózek, Heiko Becker, Jessica Kohlschmidt, Dimitrios Papaioannou, Andrew J. Carroll, Clara D. Bloomfield, Gail J. Roboz, Lisa J. Sterling, Maria R. Baer, Bayard L. Powell, Ann-Kathrin Eisfeld, Jonathan E. Kolitz, Richard Stone
Publikováno v:
Blood Advances. 2:1645-1650
The probability that adult patients with de novo acute myeloid leukemia (AML) receiving intensive chemotherapy in the absence of allogeneic hematopoietic stem cell transplantation (Allo-HCT) in first complete remission (CR1) will be disease-free at 1